
****

# **Verzamel Word-document voor het ophalen van commentaar vanuit uw achterban inzake de commentaarfase**

**Conceptrichtlijn Cerebrovasculaire ziekten**

Verstuurd op :12 november 2024

Reactie voor :23 december 2024

**Naam lid:**

**Lidmaatschapsnummer:**

**Namens interne commissie/ werkgroep:**

**Bijlage 1 Conceptrichtlijnmodules cluster cerebrovasculaire ziekten**

|  |  |  |  |
| --- | --- | --- | --- |
| ***Bijlage 1 Verantwoording voor richtlijnmodules P3-P12*** | ***Paginanr.*** | ***Regelnr.*** | ***Commentaar*** |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

|  |  |  |  |
| --- | --- | --- | --- |
| ***Bijlage 1 Startpagina Richtlijn Subarachnoïdale bloeding P13-P14*** | ***Paginanr.*** | ***Regelnr.*** | ***Commentaar*** |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

|  |  |  |  |
| --- | --- | --- | --- |
| ***Bijlage 1 Module 1 Mobiliseren na een SAB P 15-P39*** | ***Paginanr.*** | ***Regelnr.*** | ***Commentaar*** |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

|  |  |  |  |
| --- | --- | --- | --- |
| ***Bijlage 1 Module 2 Cognitieve screening na een SAB P40-P57*** | ***Paginanr.*** | ***Regelnr.*** | ***Commentaar*** |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

|  |  |  |  |
| --- | --- | --- | --- |
| ***Bijlage 1 Module 3 behandeling gebarsten aneurysma, geavanceerde behandeltechnieken P58-P64*** | ***Paginanr.*** | ***Regelnr.*** | ***Commentaar*** |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

|  |  |  |  |
| --- | --- | --- | --- |
| ***Bijlage 1 Kennislacunes P65*** | ***Paginanr.*** | ***Regelnr.*** | ***Commentaar*** |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

**Bijlage 2 Conceptrichtlijnmodules bij de richtlijn herseninfarct en hersenbloeding**

|  |  |  |  |
| --- | --- | --- | --- |
| ***Bijlage 2 Samenstelling van de werkgroep P4*** | ***Paginanr.*** | ***Regelnr.*** | ***Commentaar*** |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

|  |  |  |  |
| --- | --- | --- | --- |
| ***Bijlage 2 VerantwoordingP5-P11*** | ***Paginanr.*** | ***Regelnr.*** | ***Commentaar*** |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

|  |  |  |  |
| --- | --- | --- | --- |
| ***Bijlage 2 Module Plaatjesaggregatieremmers Acute fase P12-P31*** | ***Paginanr.*** | ***Regelnr.*** | ***Commentaar*** |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

|  |  |  |  |
| --- | --- | --- | --- |
| ***Bijlage 2 Module Plaatjesaggregatieremmers Chronische fase P32-P54*** | ***Paginanr.*** | ***Regelnr.*** | ***Commentaar*** |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

|  |  |  |  |
| --- | --- | --- | --- |
| ***Bijlage 2 Module Plaatjesaggregatieremmers Farmogenetica en clopidogrel P55-P75*** | ***Paginanr.*** | ***Regelnr.*** | ***Commentaar*** |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

**Bijlage 3 Submodule post-operatieve monitoring na carotisendarteriectomie (CEA)**

|  |  |  |  |
| --- | --- | --- | --- |
| ***Bijlage 3 Submodule postoperatieve monitoring na carotisendarteriectomie (CEA) P1-P21*** | ***Paginanr.*** | ***Regelnr.*** | ***Commentaar*** |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

|  |  |  |  |
| --- | --- | --- | --- |
| ***Overig commentaar*** | ***Paginanr.*** | ***Regelnr.*** | ***Commentaar*** |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |